These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens. Zhao L; Guo M; Sneige N; Gong Y Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458 [TBL] [Abstract][Full Text] [Related]
5. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Mhawech-Fauceglia P; Wang D; Samrao D; Godoy H; Ough F; Liu S; Pejovic T; Lele S Gynecol Oncol; 2012 Oct; 127(1):198-201. PubMed ID: 22705448 [TBL] [Abstract][Full Text] [Related]
6. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors. Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169 [TBL] [Abstract][Full Text] [Related]
7. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305 [TBL] [Abstract][Full Text] [Related]
8. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Ordóñez NG Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794 [TBL] [Abstract][Full Text] [Related]
9. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Nonaka D; Chiriboga L; Soslow RA Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243 [TBL] [Abstract][Full Text] [Related]
10. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison. Ozcan A; Liles N; Coffey D; Shen SS; Truong LD Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345 [TBL] [Abstract][Full Text] [Related]
11. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma]. Xiang L; Li J; Wang LJ; Zheng WX; Kong BH Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases. Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549 [TBL] [Abstract][Full Text] [Related]
13. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C; McCluggage WG Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer genome sequencing unveils findings. Brower V J Natl Cancer Inst; 2011 Sep; 103(17):1288-90. PubMed ID: 21852263 [No Abstract] [Full Text] [Related]
15. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin. Tacha D; Qi W; Zhou D; Bremer R; Cheng L Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948 [TBL] [Abstract][Full Text] [Related]
16. Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review. Roberts DE; Lombard CM Int J Gynecol Pathol; 2013 Sep; 32(5):459-63. PubMed ID: 23896710 [TBL] [Abstract][Full Text] [Related]
17. In vivo tumor growth of high-grade serous ovarian cancer cell lines. Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922 [TBL] [Abstract][Full Text] [Related]
18. PAX2 and PAX8: useful markers for metastatic effusions. Waters L; Crumley S; Truong L; Mody D; Coffey D Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997 [TBL] [Abstract][Full Text] [Related]
19. Can molecular diagnostics usher in a new era for screening, diagnosis, and treatment of ovarian cancer? Mutch DG Obstet Gynecol; 2014 Nov; 124(5):870-872. PubMed ID: 25437712 [No Abstract] [Full Text] [Related]
20. Value of PAX 8 immunostaining in tumor diagnosis: a review and update. Ordóñez NG Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]